Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group
在既往未接受治疗的中危慢性淋巴细胞白血病患者中,以可测量的残余病灶为指导,比较伊布替尼联合维奈克拉与FCR方案的疗效:一项来自FILO组的II期随机试验(ERADIC)。
期刊:EClinicalMedicine
影响因子:10
doi:10.1016/j.eclinm.2025.103707
Quinquenel, Anne; Letestu, Rémi; Le Garff-Tavernier, Magali; Morisset, Stéphane; Subtil, Fabien; Aurran, Thérèse; Laribi, Kamel; Cymbalista, Florence; Lévy, Vincent; Simon, Laurence; Roos-Weil, Damien; Leblond, Véronique; Dilhuydy, Marie-Sarah; Tomowiak, Cécile; Dartigeas, Caroline; Guièze, Romain; Tournilhac, Olivier; Ferrant, Emmanuelle; de Guibert, Sophie; Feugier, Pierre; Merabet, Fatiha; Leprêtre, Stéphane; Carassou, Philippe; Gay, Julie; Hivert, Bénédicte; Fornecker, Luc-Matthieu; Dupuis, Jehan; Molina, Lysiane; Villemagne, Bruno; Cartron, Guillaume; Drenou, Bernard; Mahé, Beatrice; Benbrahim, Omar; Cahu, Xavier; Portois, Christelle; Ysebaert, Loïc; Nguyen-Khac, Florence; Dahmani, Abdelmalek; Quiney, Claire; Rouillé, Valérie; Delmer, Alain; Michallet, Anne-Sophie